Atara Biotherapeutics ATRA

Jump To Section

    $

    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    .
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    +$0.02 (+0.29%)Past DayToday's Volume:
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    ,
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0

    Relative Strength Index (RSI)

    - The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.

    - The RSI is calculated using the following formula:

    RSI = 100 - (100 / (1 + RS))

    Where RS is the ratio of the average gains to the average losses over a specified period.

    - The default time period used is 14 days.

    - RSI values range between 0 and 100.

    RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)

    RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)

    RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.

    About

    Business overview of Atara Biotherapeutics (ATRA)
    Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).

    Key Insights

    Critical company metrics and information

    • Latest Closing Price

      $6.9

    • Market Cap

      $39.74 Million

    • Price-Earnings Ratio

      0.19

    • Total Outstanding Shares

      5.76 Million Shares

    • Total Employees

      159

    • Dividend

      No dividend

    • IPO Date

      October 16, 2014

    • SIC Description

      Biological Products, (no Disgnostic Substances)

    • Primary Exchange

      NASDAQ

    • Type

      Common Stock

    • Headquarters

      1280 rancho conejo blvd, Thousand oaks, CA, 91320

    • Homepage

      https://www.atarabio.com

    Historical Stock Splits

    If you bought 25 shares of ATRA before June 20, 2024, you'd have 1 share today.
    Execution DateSplit Amount
    June 20, 20241-for-25 (Reverse Split)

    Cash Flow Statement

    October 1, 2023 to September 30, 2024
    MetricValue
    Net Cash Flow$-18.34 Million
    Net Cash Flow From Investing Activities, Continuing$15.19 Million
    Net Cash Flow From Investing Activities$15.19 Million
    Net Cash Flow From Financing Activities$61.12 Million
    Net Cash Flow, Continuing$-18.34 Million
    Net Cash Flow From Operating Activities$-94.65 Million

    Income Statement

    October 1, 2023 to September 30, 2024
    MetricValue
    Preferred Stock Dividends And Other Adjustments$0
    Research and Development$172.36 Million
    Basic Average Shares$115.05 Million
    Income/Loss From Continuing Operations Before Tax$-133.14 Million
    Operating Income/Loss$-131.20 Million
    Net Income/Loss Attributable To Parent$-133.16 Million

    Comprehensive Income

    October 1, 2023 to September 30, 2024
    MetricValue
    Comprehensive Income/Loss Attributable To Parent$-132.57 Million
    Comprehensive Income/Loss$-132.57 Million
    Comprehensive Income/Loss Attributable To Noncontrolling Interest$0
    Other Comprehensive Income/Loss$593,000

    Balance Sheet

    October 1, 2023 to September 30, 2024
    MetricValue
    Liabilities And Equity$142.71 Million
    Accounts Payable$2.15 Million
    Equity Attributable To Noncontrolling Interest$0
    Fixed Assets$1.66 Million
    Equity$-90.54 Million
    Liabilities$233.25 Million

    Historical Dividends

    Announcement DatePayment DateRecord DateAmountFrequency
    No historical dividends

    Recent Headlines From The Web

    Latest news, press releases, and media coverage about ATRA from trusted financial sources
      Boost your savings and earn 4.15% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
      All TickersEarnings CalendarNews ArticlesAbout UsPrivacy & Cookies Info

      ⓒ 2025 Financhle. All Rights Reserved.